Collectively, these studies indicate that TRK inhibitors may offer innovative avenues for CFS treatment by targeting ETV6-NTRK3 activation inhibition. This evidence concerns the gene NTRK3 and myalgic encephalomeyelitis/chronic fatigue syndrome.